Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | ADH1B | P00325 | 1/20 | 0.41 |
| ▸ | ADH1C | P00326 | 1/20 | 0.41 |
| ▸ | ADH1A | P07327 | 1/20 | 0.41 |
| ▸ | ADH7 | P40394 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | SLC40A1 | Q9NP59 | 7/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31064603 | 0.83 | KDM1A (0.51) | KDM1AMAOAMAOBCNR2MAPK1 | |
| SCHEMBL657873 | 0.79 | ADH1B (0.41) | ADH1BADH1CADH1AADH7ADORA2A | |
| SCHEMBL4224354 | 0.79 | ALDH1A1 (0.53) | KDM1AADH1BADH1CADH1AADH7 | |
| SCHEMBL4857487 | 0.79 | ADH1B (0.41) | ADH1BADH1CADH1AADH7MAPK1 | |
| SCHEMBL29796409 | 0.77 | KDM1A (0.40) | KDM1AMAOAMAOBKDM4E | |
| SCHEMBL1812109 | 0.77 | KDM1A (0.40) | KDM1AMAOAMAOBKDM4E | |
| SCHEMBL13680813 | 0.76 | KDM1A (0.40) | KDM1AMAOAMAOBKDM4E | |
| SCHEMBL2260570 | 0.76 | KDM1A (0.47) | KDM1AMAOAMAOBCNR2MAPK1 | |
| SCHEMBL19450454 | 0.76 | KDM1A (0.49) | KDM1AMAOAMAOBCNR2MAPK1 | |
| SCHEMBL2712754 | 0.76 | KDM1A (0.49) | KDM1AMAOAMAOBCNR2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738041-B2 | Ferroportin inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2020-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10738041-B2 | Ferroportin inhibitors | SLC40A1, HAMP, TFRC | KDM1A 4579/4885MAOA 1766/4885MAOB 1306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.